P370 A randomised controlled trial of acceptance and commitment therapy for the treatment of stress in inflammatory bowel disease

  • Mulcahy H
  • Wynne B
  • McHugh L
  • et al.
N/ACitations
Citations of this article
54Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

S266 Poster presentations mod (n=6) or placebo (n=2), starting at 0.1mg. Following screening (21 days), single doses were administered on Day 1 and observations undertaken until at least Day 7. In Study 002, up to 12 subjects in each of 3 cohorts (0.7, 1.35 and 2.0mg) received etrasimod (n=10) or placebo (n=2) for 21 days. Dosing in Cohorts 4 and 5 started at 0.35 and 0.5mg for 7 days with titration to 2.0 and 3.0mg, respectively. Results: In single doses, etrasimod was well tolerated at 0.1, 0.35, 1 and 3mg. Mild-to-moderate headache (1/6-3/6 of subjects) and contact dermatitis (1/6-2/6) were the most commonly reported AEs, occurring with similar/lower frequency to placebo (2/3 each). In the 5mg cohort, 4 events of first or second degree AV block, with and without bradycardia, occurred in 3/6 subjects; although asymp-tomatic, further dose escalation was stopped. Dose-related declines in blood pressure and heart rate from baseline (vs placebo) were statistically significant with 3.0 and 5.0mg doses only (p<0.05); all resolved without intervention. With multiple dosing, common AEs with etrasimod versus placebo included contact dermatitis (1/10-7/10 of subjects vs. 6/10), constipation (2/10-3/10% vs. 0), headache (1/10-3/10% vs. 4/10) and diarrhoea (2/10-3/10% vs. 1/10). These were mild-to-moderate, and not dose related. Small asymptomatic declines in blood pressure and heart rate were noted. 3 subjects developed first degree AV block (placebo: 1; 2mg: 1; 0.5/3mg: 1). No serious AEs or deaths were reported. Single etrasimod doses of 3mg and 5mg decreased total peripheral blood lymphocyte counts to 52.5% and 35.9% of baseline and with time to nadir of ∼15 hours and ∼11 hours post-dose, respectively. With multiple dosing, etrasimod had a dose-dependent effect on lymphocyte lowering, plateauing at 2mg QD. Median reduction in lymphocyte counts was ∼67% for the higher doses (2 and 3mg QD for 21 days). For both studies, mean counts returned to baseline levels within 7 days of dosing discontin-uation. Conclusions: In Phase I studies, etrasimod was well tolerated and modulated lymphocyte levels when administered orally at dose levels ≤3mg in healthy volunteers. These findings support further evaluation of this S1P modulator in clinical studies. Background: The inflammatory bowel diseases are associated with high levels of psychological stress. Acceptance and commitment therapy (ACT) is a psychological intervention that comprises acceptance and mindfulness procedures along with commitment and behaviour-change strategies to increase psychological flexibility and reduce stress. The aim of this study was to determine the effect of ACT on stress in IBD patients. Methods: Ninety five patients (mean age 40 years; 42 male) with quiescent or mildly active IBD were randomly assigned to an eight week ACT course (n=47) or to a control group (n=48) stratified by disease type and gender. Clinical, demographic, disease activity, biochemical (including CRP and faecal calprotectin) and psychological data were collected at i) baseline, ii) post-intervention (8 weeks) and iii) 20 weeks. Patients on antidepressants, those with psychiatric disorders or those who had received steroids over the previous three

Cite

CITATION STYLE

APA

Mulcahy, H., Wynne, B., McHugh, L., Rowan, C., Byrne, K., Keegan, D., … Dooley, B. (2017). P370 A randomised controlled trial of acceptance and commitment therapy for the treatment of stress in inflammatory bowel disease. Journal of Crohn’s and Colitis, 11(suppl_1), S266–S266. https://doi.org/10.1093/ecco-jcc/jjx002.495

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free